ArticleBMC psychiatry2025
Cognitive impairment in bipolar disorder associated with abnormal serum short-chain fatty acids and cytokines.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut dysbiosis and systemic inflammation in elderly hypertensive patients with amnestic mild cognitive impairment.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe investigated changes in serum short-chain fatty acids (SCFAs) levels in patients with bipolar disorder (BD) and explored the relationship between these levels and peripheral cytokines and their impact on cognitive function.
methodsThis study enrolled 64 patients with BD and 54 healthy controls (HCs) in a case-control design. Levels of 16 SCFAs and 9 cytokines in serum were measured via targeted metabolomics and Luminex multiplex assay, respectively. A subgroup (33 BD and 38 HCs) completed the MATRICS Consensus Cognitive Battery (MCCB) for neurocognitive assessment. Multiple linear regression and mediation analysis were used to examine the cross-sectional relationships among SCFAs (independent variable), cytokines (mediator), and cognitive function (dependent variable).
resultsSerum propionic acid (PA) and butyric acid (BA) were elevated, whereas isovaleric acid (IVA), caproic acid (CA), and octanoic acid (OA) were reduced in patients with BD compared to HCs. Multiple linear regression models indicated that CA, IVA, Interleukin (IL)-6, and IL-8 collectively explained 16.6%–41.4% of the variance in Trail Making Test (TMT), Neuropsychological Assessment Battery (NAB) and Wechsler Memory Scale (WMS) cognitive tests. Mediation analysis revealed that CA and IVA contributed to impairments in working memory and reasoning (as measured by WMS and NAB) by partially mediating the upregulation of IL-6 and IL-8, with the proportion mediated ranging from 5.1% to 21.2%. A random forest model based on distinct SCFAs and cytokines accurately distinguished BD patients from HCs (AUC = 0.98).
conclusionBy integrating multi-omics with mediation analysis, our study is the first to delineate a novel gut-brain pathway in BD, wherein maladjusted SCFAs appear to drive cognitive deficits via pro-inflammation. This mechanistic insight suggests that augmenting beneficial SCFA-producing bacteria or targeting IL-6/IL-8 could be potential strategies worthy of future validation for alleviating cognitive impairment in BD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.